Palisade Bio PALI 深 沪
等待开盘 07-24 09:30:00 美东时间
2.02
+0.120
+6.32%
华盛通- 最 高2.20
- 今 开2.03
- 成交量 591.19万股
- 最 低 1.97
- 昨 收 1.90
- 总市值 35.06万
- 52周最高 2.855
- 市盈率 静 --
- 换手率 3.41%
- 52周最低 0.53
- 委 比 -73.17%
- 总股本 0.00亿
- 历史最高 18405.00
- 量 比 2.52
- 振 幅 12.11%
- 历史最低 0.53
- 每 手 1
- 风险率 0.49%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 谷歌绩后分歧大！4家大行上调、10家下调目标价；特斯拉遭8家大行下调目标价；ServiceNow、德州仪器、西屋制动、AT&T、CSX等获多家大行上调目标价
今日重点评级关注：伯恩斯坦：维持ServiceNow"跑赢大市"评级，目标价从236美元升至248美元；HC Wainwright & Co.：维持NovoCure"买入"评级，目标价从46美元升至52美元
今天 11:37
Palisade Bio jumps following Oppenheimer outperform initiation
Oppenheimer has initiated Palisade Bio (PALI) at outperforming, sending the stock ~14% higher in Thursday morning trading. The investment bank has an $8 price target (321% upside based on July 22 clos...
07-23 23:13
Oppenheimer Initiates Coverage On Palisade Bio with Outperform Rating, Announces Price Target of $8
Oppenheimer analyst Leland Gershell initiates coverage on Palisade Bio (NASDAQ:PALI) with a Outperform rating and announces Price Target of $8.
07-23 18:57
Palisade Bio to Participate in the Leerink Partners Therapeutics Forum
Palisade Bio, Inc. announced that its CEO, JD Finley, and President & Chief Medical Officer, Dr. Mitchell Jones, will participate in the Leerink Partners Therapeutics Forum in Boston on July 14-15. They will meet with institutional investors to discuss the company's clinical strategy, progress with PALI-2108, and upcoming milestones in its inflammatory bowel disease programs. Palisade Bio is advancing a next-generation oral PDE4 inhibitor prodrug...
07-10 13:00
分析师解读医疗健康企业：Evommune, Inc.（EVMN）与Palisade Bio（PALI）
医疗保健领域近期出现看涨信号，两家生物科技公司获分析师给出买入评级。 Evommune Inc.（EVMN）相关关键信息： 摩根士丹利维持买入评级，目标价2...
06-30 19:18
Palisade Bio Says FDA Clears IND Application For PALI-2108, Enabling Initiation Of Global Phase 2 ASCENTRA-UC Clinical Trial In Patients With Active Ulcerative Colitis
ASCENTRA-UC expected to enroll up to 204 patients with moderately to severely active ulcerative colitis across North America and Europe First patient enrollment anticipated in the second half of 2026; primary efficacy results expected in the second half of 2027 IND clearance marks a major developmen...
06-29 20:36
Palisade Bio Shareholders Approve Charter Amendments, Governance Matters
Palisade Bio ( ($PALI) ) just unveiled an announcement. At its annual meeting o...
06-12 06:53
Palisade Bio To Present Novel PDE4 Inhibitor Strategy For Fibrostenotic Crohn's Disease At NYAS Fibrosis Symposium
Presentation to highlight fibrostenotic Crohn's disease biology and the potential of a locally bioactivated PDE4 inhibitor prodrug approachDenver, CO, June 09, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI)
06-09 20:46
Verra Mobility, Zscaler, Box And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Stock futures rise on Wednesday, with Verra Mobility's shares plunging 45% after Avis Budget Group terminated its agreement with the company. Other stocks moving lower in pre-market trading include Zscaler, Brain, LG Display, Zepp Health, Globalfoundries, Posco Holdings, Insulet, Palisade Bio, Satellogic, and Box.
05-27 20:02
Palisade Bio to Participate in the Jefferies Global Healthcare Conference
Palisade Bio, Inc. announced that its CEO JD Finley and President & Chief Medical Officer Dr. Mitchell Jones will present at the Jefferies Global Healthcare Conference on June 2-4, 2026, in New York. The company’s presentation is scheduled for June 4, 2026, at 3:45 PM ET, and a live webcast will be available on the Events page of the Investors section of Palisade Bio’s website. Management will also participate in one-on-one meetings with qualifie...
05-27 13:00
